Atlas Trials

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

Clinical trial NCT07032272 · COMPLETED

Trial details

NCT number
NCT07032272
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Autoimmune and Chronic Inflammatory Diseases
Start date
2025-07-23
Primary completion
2025-10-12
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.